<p>Clal Insurance Enterprises Holdings Ltd 在最近向美國證券交易委員會（SEC）提交的文件中表示，在第二季度將其在 Teva Pharmaceutical Industries Ltd.（紐約證券交易所代碼：TEVA - 免費報告）的持股比例降低了 14.5%。該機構投資者在季度內出售了 5,491,385 股後，持有 32,362,683 股該公司的股票。Teva Pharmaceutical Industries 大約佔 Clal Insurance Enterprises Holdings Ltd. 持有資產的 5.3%，是其第四大持倉。截至最近向 SEC 提交的文件，Clal Insurance Enterprises Holdings Ltd. 持有 Teva Pharmaceutical Industries 約 2.82% 的股份，價值 543,026,000 美元。</p>
<ul>
<li>MarketBeat 週報 – 02/03 - 02/07</li>
</ul>
<p>其他幾家對沖基金最近也買賣了 TEVA 的股票。Bourgeon Capital Management LLC 在第二季度將其在 Teva Pharmaceutical Industries 的持倉增加了 100.7%。Bourgeon Capital Management LLC 目前持有 723,974 股該公司的股票，價值 12,134,000 美元，此前在上個季度又購買了 363,252 股。Amundi 在第一季度將其在 Teva Pharmaceutical Industries 的股份增加了 18.5%。Amundi 目前持有 678,758 股該公司的股票，價值 10,080,000 美元，此前在上個季度又購買了 105,846 股。IFM Investors Pty Ltd 在第二季度將其在 Teva Pharmaceutical Industries 的持股增加了 9.4%。IFM Investors Pty Ltd 目前持有 226,534 股該公司的股票，價值 3,797,000 美元，此前在上個季度又購買了 19,447 股。Jump Financial LLC 在第一季度將其在 Teva Pharmaceutical Industries 的持倉提高了 172.1%。Jump Financial LLC 目前持有 1,325,526 股該公司的股票，價值 20,373,000 美元，此前在上個季度又購買了 838,423 股。最後，Financial Sense Advisors Inc. 在第一季度將其在 Teva Pharmaceutical Industries 的股份增加了 63.5%。Financial Sense Advisors Inc. 目前持有 405,421 股該公司的股票，價值 6,231,000 美元，此前在該期間又購買了 157,421 股。對沖基金和其他機構投資者持有該公司 54.05% 的股票。</p>
<h2>Teva Pharmaceutical Industries 股價上漲 1.1%</h2>
<p>TEVA 股票週三開盤價為 24.86 美元。該公司的速動比率為 0.77，流動比率為 1.06，債務與股本比率為 2.45。該公司的市值為 285.1 億美元，市盈率為 -155.38，PEG 比率為 1.11，貝塔值為 0.70。該公司的 50 日簡單移動平均線為 20.60 美元，200 日簡單移動平均線為 18.37 美元。Teva Pharmaceutical Industries Ltd. 的 52 周最低價為 12.47 美元，52 周最高價為 26.38 美元。</p>
<ul>
<li>Teva Pharma：為什麼這家仿製藥巨頭現在是一個明智的投資</li>
</ul>
<p>Teva Pharmaceutical Industries（紐約證券交易所代碼：TEVA - 獲取免費報告）最近在 11 月 5 日（星期三）發佈了其財報。該公司報告本季度每股收益為 0.78 美元，超出分析師一致預期的 0.68 美元，超出幅度為 0.10 美元。該公司本季度的收入為 44.8 億美元，而分析師預期為 43.6 億美元。Teva Pharmaceutical Industries 的股本回報率為 46.10%，淨利潤率為 -0.95%。該公司的季度收入較去年同期增長了 3.4%。去年同期，該公司每股收益為 0.69 美元。Teva Pharmaceutical Industries 已將其 2025 財年的指導目標設定為每股收益 2.550-2.650 美元。根據分析師的平均預期，Teva Pharmaceutical Industries Ltd. 預計本年度每股收益為 2.5 美元。</p>
<h2>內部交易活動</h2>
<p>在相關消息中，董事 Roberto Mignone 於 11 月 6 日（星期四）出售了 200,000 股該股票。股份以平均價格 24.11 美元出售，總交易額為 4,822,000.00 美元。交易完成後，該董事持有 495,000 股該公司的股票，估值約為 11,934,450 美元。這代表其持倉減少了 28.78%。該交易已在向證券交易委員會提交的文件中披露，相關文件可通過 SEC 網站訪問。內部人士持有該公司 0.49% 的股票。</p>
<h2>分析師設定新目標價</h2>
<ul>
<li>2 只准備在 2025 年飆升的仿製藥股票</li>
</ul>
<p>幾位分析師對該股票發表了評論。摩根大通將 Teva Pharmaceutical Industries 的目標價從 26.00 美元上調至 28.00 美元，並在 11 月 6 日的研究報告中給予該股票 “增持” 評級。華爾街 Zen 在 10 月 11 日的報告中將 Teva Pharmaceutical Industries 的評級從 “買入” 上調至 “強力買入”。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Teva Pharmaceutical Industries 的 “賣出（d-）” 評級。最後，瑞銀集團在 9 月 24 日的研究報告中將 Teva Pharmaceutical Industries 的目標價從 23.00 美元上調至 26.00 美元，並給予該股票 “買入” 評級。兩位投資分析師對該股票給予 “強力買入” 評級，六位給予 “買入” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，Teva Pharmaceutical Industries 目前的共識評級為 “買入”，平均目標價為 25.86 美元。</p>
<p><strong>閲讀我們關於 TEVA 的最新報告</strong></p>
<h2>Teva Pharmaceutical Industries 公司簡介</h2>
<p>（免費報告）</p>
<p>Teva Pharmaceutical Industries Limited 在北美、歐洲、以色列及國際市場開發、生產、營銷和分銷仿製藥、專科藥物和生物製藥產品。它提供各種劑型的仿製藥，如片劑、膠囊、注射劑、吸入劑、液體、透皮貼劑、軟膏和乳膏；無菌產品、激素、高效藥物和細胞毒性物質的注射劑和固體劑型；以及與醫療器械和組合產品的仿製藥。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過戴瓦製藥</li>
<li>什麼是 MarketRank™？如何使用它</li>
<li>感恩節餐桌上有什麼？每道菜的股票推薦</li>
<li>如何做空納斯達克：簡單易懂的指南</li>
<li>為什麼家得寶的困境可能是長期投資者的機會</li>
<li>5 只值得考慮的高評級分紅股票</li>
<li>高通的多頭們正面臨越來越小的錯誤空間</li>
</ul>
<p><strong>想看看其他對 TEVA 持有的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com 獲取戴瓦製藥有限公司（NYSE:TEVA - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRFVkE?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRFVkE"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在戴瓦製藥嗎？</h2>
<p>在考慮戴瓦製藥之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而戴瓦製藥並不在名單上。</p>
<p>雖然戴瓦製藥目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

梯瓦制藥

<p>Clal Insurance 在第二季度將其在梯瓦製藥的股份減少了 14.5%，目前持有 3236 萬股，價值 5.43 億美元。梯瓦的股票是 Clal 的第四大持倉。其他投資者也調整了持倉，對沖基金持有梯瓦 54.05% 的股票。梯瓦第三季度的收益超出預期，報告每股收益為 0.78 美元，營收為 44.8 億美元。分析師提高了目標價，摩根大通將目標價設定為 28.00 美元。內部人士羅伯託·米尼翁出售了 20 萬股。梯瓦的股票開盤價為 24.86 美元，市值為 285.1 億美元</p>

<p>Clal Insurance Enterprises Holdings Ltd lowered its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 14.5% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 32,362,683 shares of the company's stock after selling 5,491,385 shares during the quarter. Teva Pharmaceutical Industries makes up about 5.3% of Clal Insurance Enterprises Holdings Ltd's holdings, making the stock its 4th biggest position. Clal Insurance Enterprises Holdings Ltd owned about 2.82% of Teva Pharmaceutical Industries worth $543,026,000 as of its most recent filing with the SEC.</p>
<div class="lb-trans"><p>Clal Insurance Enterprises Holdings Ltd 在最近向美國證券交易委員會（SEC）提交的文件中表示，在第二季度將其在 Teva Pharmaceutical Industries Ltd.（紐約證券交易所代碼：TEVA - 免費報告）的持股比例降低了 14.5%。該機構投資者在季度內出售了 5,491,385 股後，持有 32,362,683 股該公司的股票。Teva Pharmaceutical Industries 大約佔 Clal Insurance Enterprises Holdings Ltd. 持有資產的 5.3%，是其第四大持倉。截至最近向 SEC 提交的文件，Clal Insurance Enterprises Holdings Ltd. 持有 Teva Pharmaceutical Industries 約 2.82% 的股份，價值 543,026,000 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 02/03 - 02/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週報 – 02/03 - 02/07</li>
</ul>
</div><p>Several other hedge funds also recently bought and sold shares of TEVA. Bourgeon Capital Management LLC increased its position in Teva Pharmaceutical Industries by 100.7% during the 2nd quarter. Bourgeon Capital Management LLC now owns 723,974 shares of the company's stock worth $12,134,000 after purchasing an additional 363,252 shares in the last quarter. Amundi boosted its stake in shares of Teva Pharmaceutical Industries by 18.5% during the 1st quarter. Amundi now owns 678,758 shares of the company's stock worth $10,080,000 after purchasing an additional 105,846 shares during the last quarter. IFM Investors Pty Ltd grew its holdings in shares of Teva Pharmaceutical Industries by 9.4% during the second quarter. IFM Investors Pty Ltd now owns 226,534 shares of the company's stock worth $3,797,000 after buying an additional 19,447 shares in the last quarter. Jump Financial LLC raised its position in shares of Teva Pharmaceutical Industries by 172.1% in the first quarter. Jump Financial LLC now owns 1,325,526 shares of the company's stock valued at $20,373,000 after buying an additional 838,423 shares during the last quarter. Finally, Financial Sense Advisors Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 63.5% during the first quarter. Financial Sense Advisors Inc. now owns 405,421 shares of the company's stock valued at $6,231,000 after buying an additional 157,421 shares during the period. Hedge funds and other institutional investors own 54.05% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家對沖基金最近也買賣了 TEVA 的股票。Bourgeon Capital Management LLC 在第二季度將其在 Teva Pharmaceutical Industries 的持倉增加了 100.7%。Bourgeon Capital Management LLC 目前持有 723,974 股該公司的股票，價值 12,134,000 美元，此前在上個季度又購買了 363,252 股。Amundi 在第一季度將其在 Teva Pharmaceutical Industries 的股份增加了 18.5%。Amundi 目前持有 678,758 股該公司的股票，價值 10,080,000 美元，此前在上個季度又購買了 105,846 股。IFM Investors Pty Ltd 在第二季度將其在 Teva Pharmaceutical Industries 的持股增加了 9.4%。IFM Investors Pty Ltd 目前持有 226,534 股該公司的股票，價值 3,797,000 美元，此前在上個季度又購買了 19,447 股。Jump Financial LLC 在第一季度將其在 Teva Pharmaceutical Industries 的持倉提高了 172.1%。Jump Financial LLC 目前持有 1,325,526 股該公司的股票，價值 20,373,000 美元，此前在上個季度又購買了 838,423 股。最後，Financial Sense Advisors Inc. 在第一季度將其在 Teva Pharmaceutical Industries 的股份增加了 63.5%。Financial Sense Advisors Inc. 目前持有 405,421 股該公司的股票，價值 6,231,000 美元，此前在該期間又購買了 157,421 股。對沖基金和其他機構投資者持有該公司 54.05% 的股票。</p>
</div><h2>Teva Pharmaceutical Industries Trading Up 1.1%</h2>
<div class="lb-trans"><h2>Teva Pharmaceutical Industries 股價上漲 1.1%</h2>
</div><p>TEVA stock opened at $24.86 on Wednesday. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. The company has a market cap of $28.51 billion, a price-to-earnings ratio of -155.38, a PEG ratio of 1.11 and a beta of 0.70. The business has a fifty day simple moving average of $20.60 and a 200-day simple moving average of $18.37. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $26.38.</p>
<div class="lb-trans"><p>TEVA 股票週三開盤價為 24.86 美元。該公司的速動比率為 0.77，流動比率為 1.06，債務與股本比率為 2.45。該公司的市值為 285.1 億美元，市盈率為 -155.38，PEG 比率為 1.11，貝塔值為 0.70。該公司的 50 日簡單移動平均線為 20.60 美元，200 日簡單移動平均線為 18.37 美元。Teva Pharmaceutical Industries Ltd. 的 52 周最低價為 12.47 美元，52 周最高價為 26.38 美元。</p>
</div><ul>
<li>Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now</li>
</ul>
<div class="lb-trans"><ul>
<li>Teva Pharma：為什麼這家仿製藥巨頭現在是一個明智的投資</li>
</ul>
</div><p>Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, November 5th. The company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.68 by $0.10. The firm had revenue of $4.48 billion for the quarter, compared to analysts' expectations of $4.36 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The firm's revenue for the quarter was up 3.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.69 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS. On average, equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.</p>
<div class="lb-trans"><p>Teva Pharmaceutical Industries（紐約證券交易所代碼：TEVA - 獲取免費報告）最近在 11 月 5 日（星期三）發佈了其財報。該公司報告本季度每股收益為 0.78 美元，超出分析師一致預期的 0.68 美元，超出幅度為 0.10 美元。該公司本季度的收入為 44.8 億美元，而分析師預期為 43.6 億美元。Teva Pharmaceutical Industries 的股本回報率為 46.10%，淨利潤率為 -0.95%。該公司的季度收入較去年同期增長了 3.4%。去年同期，該公司每股收益為 0.69 美元。Teva Pharmaceutical Industries 已將其 2025 財年的指導目標設定為每股收益 2.550-2.650 美元。根據分析師的平均預期，Teva Pharmaceutical Industries Ltd. 預計本年度每股收益為 2.5 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部交易活動</h2>
</div><p>In related news, Director Roberto Mignone sold 200,000 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the completion of the sale, the director owned 495,000 shares of the company's stock, valued at approximately $11,934,450. This represents a 28.78% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Insiders own 0.49% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，董事 Roberto Mignone 於 11 月 6 日（星期四）出售了 200,000 股該股票。股份以平均價格 24.11 美元出售，總交易額為 4,822,000.00 美元。交易完成後，該董事持有 495,000 股該公司的股票，估值約為 11,934,450 美元。這代表其持倉減少了 28.78%。該交易已在向證券交易委員會提交的文件中披露，相關文件可通過 SEC 網站訪問。內部人士持有該公司 0.49% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><ul>
<li>2 Generic Drug Stocks Ready to Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只准備在 2025 年飆升的仿製藥股票</li>
</ul>
</div><p>Several analysts have commented on the stock. JPMorgan Chase &amp; Co. lifted their target price on shares of Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the stock an &#34;overweight&#34; rating in a research note on Thursday, November 6th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a report on Saturday, October 11th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Finally, UBS Group increased their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, September 24th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of &#34;Buy&#34; and an average price target of $25.86.</p>
<div class="lb-trans"><p>幾位分析師對該股票發表了評論。摩根大通將 Teva Pharmaceutical Industries 的目標價從 26.00 美元上調至 28.00 美元，並在 11 月 6 日的研究報告中給予該股票 “增持” 評級。華爾街 Zen 在 10 月 11 日的報告中將 Teva Pharmaceutical Industries 的評級從 “買入” 上調至 “強力買入”。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Teva Pharmaceutical Industries 的 “賣出（d-）” 評級。最後，瑞銀集團在 9 月 24 日的研究報告中將 Teva Pharmaceutical Industries 的目標價從 23.00 美元上調至 26.00 美元，並給予該股票 “買入” 評級。兩位投資分析師對該股票給予 “強力買入” 評級，六位給予 “買入” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，Teva Pharmaceutical Industries 目前的共識評級為 “買入”，平均目標價為 25.86 美元。</p>
</div><p><strong>Read Our Latest Report on TEVA</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 TEVA 的最新報告</strong></p>
</div><h2>Teva Pharmaceutical Industries Company Profile</h2>
<div class="lb-trans"><h2>Teva Pharmaceutical Industries 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.</p>
<div class="lb-trans"><p>Teva Pharmaceutical Industries Limited 在北美、歐洲、以色列及國際市場開發、生產、營銷和分銷仿製藥、專科藥物和生物製藥產品。它提供各種劑型的仿製藥，如片劑、膠囊、注射劑、吸入劑、液體、透皮貼劑、軟膏和乳膏；無菌產品、激素、高效藥物和細胞毒性物質的注射劑和固體劑型；以及與醫療器械和組合產品的仿製藥。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Teva Pharmaceutical Industries</li>
<li>What is MarketRank™? How to Use it</li>
<li>What’s on the Thanksgiving Table? A Stock Pick for Every Course</li>
<li>How to Short Nasdaq: An Easy-to-Follow Guide</li>
<li>Why Home Depot’s Pain Could Be a Long-Term Investor’s Gain</li>
<li>5 Top Rated Dividend Stocks to Consider</li>
<li>Qualcomm’s Bulls Are Running Out of Room to Be Wrong</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過戴瓦製藥</li>
<li>什麼是 MarketRank™？如何使用它</li>
<li>感恩節餐桌上有什麼？每道菜的股票推薦</li>
<li>如何做空納斯達克：簡單易懂的指南</li>
<li>為什麼家得寶的困境可能是長期投資者的機會</li>
<li>5 只值得考慮的高評級分紅股票</li>
<li>高通的多頭們正面臨越來越小的錯誤空間</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TEVA?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 TEVA 持有的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com 獲取戴瓦製藥有限公司（NYSE:TEVA - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRFVkE" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=TEVA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Teva Pharmaceutical Industries Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在戴瓦製藥嗎？</h2>
</div><p>Before you consider Teva Pharmaceutical Industries, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮戴瓦製藥之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而戴瓦製藥並不在名單上。</p>
</div><p>While Teva Pharmaceutical Industries currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然戴瓦製藥目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

梯瓦製藥有限公司 $TEVA 是 Clal Insurance Enterprises Holdings Ltd 的第四大持倉